fenfluramine has been researched along with Syndrome in 12 studies
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.
Syndrome: A characteristic symptom complex.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study reports on the long-term results for an initial cohort of patients with Sunflower syndrome who enrolled in an open-label study of low-dose fenfluramine as well as the short-term results of a second cohort." | 9.69 | Follow-up to low-dose fenfluramine for Sunflower syndrome: A non-randomized controlled trial. ( Bruno, PL; Dowless, D; Geenen, KR; Patel, S; Thiele, EA, 2023) |
| "Fenfluramine was administered to 14 outpatient children with the syndrome of autism to determine whether previously produced decreases in blood serotonin concentrations and clinical improvements could be reinstituted." | 9.05 | Study of fenfluramine in outpatients with the syndrome of autism. ( Freeman, BJ; Geller, E; Novak, P; Ritvo, ER; Schroth, P; Yokota, A; Yuwiler, A, 1984) |
| " To do so, components of the serotonin syndrome, as induced by various doses of fenfluramine, were scored both before and after a 15-day subacute regimen with these agents." | 7.67 | A comparison of the fenfluramine-induced serotonergic syndrome in rats subacutely treated with either saline or D-amphetamine. ( Hunsinger, RN; Wilson, MC, 1984) |
| "This study reports on the long-term results for an initial cohort of patients with Sunflower syndrome who enrolled in an open-label study of low-dose fenfluramine as well as the short-term results of a second cohort." | 5.69 | Follow-up to low-dose fenfluramine for Sunflower syndrome: A non-randomized controlled trial. ( Bruno, PL; Dowless, D; Geenen, KR; Patel, S; Thiele, EA, 2023) |
| "Fenfluramine was administered to 14 outpatient children with the syndrome of autism to determine whether previously produced decreases in blood serotonin concentrations and clinical improvements could be reinstituted." | 5.05 | Study of fenfluramine in outpatients with the syndrome of autism. ( Freeman, BJ; Geller, E; Novak, P; Ritvo, ER; Schroth, P; Yokota, A; Yuwiler, A, 1984) |
| " Chronic treatment of rats with D-fenfluramine has been shown to decrease the release of cortisol and fatty acids in response to stress, and to improve insulin sensitivity." | 4.79 | Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in the metabolic syndrome. ( Brindley, DN, 1995) |
| " To do so, components of the serotonin syndrome, as induced by various doses of fenfluramine, were scored both before and after a 15-day subacute regimen with these agents." | 3.67 | A comparison of the fenfluramine-induced serotonergic syndrome in rats subacutely treated with either saline or D-amphetamine. ( Hunsinger, RN; Wilson, MC, 1984) |
| "This study evaluated the behavioral elements of three 5-HT-related syndromes (intraperitoneal 5-hydroxytryptophan after intracisternal 5,7-dihydroxytryptamine (DHT), p-chloroamphetamine (PCA), fenfluramine (FF), or combinations of drugs) scored from video-tapes and their relationship to locomotor activity (LMA) photocell recording, regional monoamine concentration and S-1 receptor binding." | 3.67 | Serotonin-lesion myoclonic syndromes. II. Analysis of individual syndrome elements, locomotor activity and behavioral correlations. ( Pranzatelli, MR; Snodgrass, SR, 1986) |
| "The syndrome is characterized by insulin insensitivity and an increased control of metabolism by cortisol." | 2.38 | Neuroendocrine regulation and obesity. ( Brindley, DN, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (41.67) | 18.7374 |
| 1990's | 6 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, S | 1 |
| Geenen, KR | 1 |
| Dowless, D | 1 |
| Bruno, PL | 1 |
| Thiele, EA | 1 |
| Mira, E | 1 |
| Piacentino, G | 1 |
| Lanzi, G | 1 |
| Balottin, U | 1 |
| Fazzi, E | 1 |
| Hunsinger, RN | 1 |
| Wilson, MC | 1 |
| Ritvo, ER | 1 |
| Freeman, BJ | 1 |
| Yuwiler, A | 1 |
| Geller, E | 1 |
| Yokota, A | 1 |
| Schroth, P | 1 |
| Novak, P | 1 |
| Després, JP | 1 |
| Lemieux, S | 1 |
| Lamarche, B | 1 |
| Prud'homme, D | 1 |
| Moorjani, S | 1 |
| Brun, LD | 1 |
| Gagné, C | 1 |
| Lupien, PJ | 1 |
| Brindley, DN | 3 |
| Storlien, LH | 1 |
| Oakes, ND | 1 |
| Pan, DA | 1 |
| Kusunoki, M | 1 |
| Jenkins, AB | 1 |
| Naito, Y | 1 |
| Pranzatelli, MR | 2 |
| Rubin, G | 1 |
| Snodgrass, SR | 2 |
5 reviews available for fenfluramine and Syndrome
| Article | Year |
|---|---|
The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications.
Topics: Adipose Tissue; Cardiovascular Diseases; Fenfluramine; Humans; Hyperlipidemias; Insulin Resistance; | 1995 |
Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in the metabolic syndrome.
Topics: Animals; Fatty Acids; Fatty Acids, Nonesterified; Fenfluramine; Glucocorticoids; Humans; Hydrocortis | 1995 |
Mechanisms for the effects of benfluorex on the obese-diabetic-dyslipidemic syndrome.
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fenfluramine; Humans; Hyperlipidemias; Hypogl | 1993 |
[Neuroleptic malignant syndrome-dopamine-serotonin syndrome--the physiopathology, diagnosis, and therapy].
Topics: Animals; Appetite Depressants; Dantrolene; Dopamine D2 Receptor Antagonists; Fenfluramine; Humans; M | 1997 |
Neuroendocrine regulation and obesity.
Topics: Animals; Diabetes Complications; Endocrine Glands; Fenfluramine; Humans; Hydrocortisone; Hyperlipide | 1992 |
2 trials available for fenfluramine and Syndrome
| Article | Year |
|---|---|
Follow-up to low-dose fenfluramine for Sunflower syndrome: A non-randomized controlled trial.
Topics: Anticonvulsants; Epilepsy, Reflex; Fenfluramine; Follow-Up Studies; Helianthus; Humans; Seizures; Sy | 2023 |
Study of fenfluramine in outpatients with the syndrome of autism.
Topics: Adolescent; Autistic Disorder; Body Weight; Child; Child Development; Child, Preschool; Female; Fenf | 1984 |
5 other studies available for fenfluramine and Syndrome
| Article | Year |
|---|---|
Benign paroxysmal vertigo in childhood: a migraine equivalent.
Topics: Child; Child, Preschool; Female; Fenfluramine; Histamine; Humans; Male; Migraine Disorders; Nitrogly | 1984 |
A comparison of the fenfluramine-induced serotonergic syndrome in rats subacutely treated with either saline or D-amphetamine.
Topics: Animals; Behavior, Animal; Dextroamphetamine; Fenfluramine; Male; Rats; Rats, Inbred Strains; Recept | 1984 |
Syndromes of insulin resistance in the rat. Inducement by diet and amelioration with benfluorex.
Topics: Analysis of Variance; Animals; Diet; Dietary Carbohydrates; Dietary Fats; Disease Models, Animal; Fe | 1993 |
Serotonin-lesion myoclonic syndromes. I. Neurochemical profile and S-1 receptor binding.
Topics: 5-Hydroxytryptophan; 5,7-Dihydroxytryptamine; Amphetamines; Animals; Biogenic Amines; Brain; Brain C | 1986 |
Serotonin-lesion myoclonic syndromes. II. Analysis of individual syndrome elements, locomotor activity and behavioral correlations.
Topics: 5-Hydroxytryptophan; 5,7-Dihydroxytryptamine; Amphetamines; Animals; Dihydroxytryptamines; Drug Inte | 1986 |